Session I: Controversies in Hepatobiliary Malignancy
Treatment options for other hepatic malignancies
Article first published online: 30 DEC 2003
Copyright © 2000 American Association for the Study of Liver Diseases
Supplement: Advances and Controversies in Liver Transplantation
Volume 6, Issue Supplement 6B, pages s23–s29, November 2000
How to Cite
O'Grady, J. G. (2000), Treatment options for other hepatic malignancies. Liver Transpl, 6: s23–s29. doi: 10.1053/jlts.2000.18687
- Issue published online: 30 DEC 2003
- Article first published online: 30 DEC 2003
1. Resection rates for cholangiocarcinoma (unrelated to primary sclerosing cholangitis) have increased to 54% to 79%, and the subsequent 5-year survival rates are 24% to 31%.
2. Multimodality approaches involving various combinations of chemotherapy, irradiation, and surgery increasingly are being used to treat cholangiocarcinoma.
3. The role of liver transplantation in the management of cholangiocarcinoma is limited by the perception that it is inappropriate to use scarce organs when 5-year survival rates are 25%.
4. Liver transplantation is an important intervention in patients with tumors that remain unresectable after chemotherapy. The role of liver transplantation in patients with extrahepatic disease that responds to chemotherapy is controversial. Careful timing of surgery is required to avoid secondary drug resistance.
5. Liver transplantation has been successfully applied to a range of rare hepatic malignancies, but small numbers preclude strong recommendations on the appropriateness of this practice.